CEO Blog

Meet The Team

Behind every great company, there is a strong and cohesive team. At BioSig, this saying certainly holds true. The BioSig team unites leading executives, physicians, and scientists from prominent hospitals, healthcare programs, Fortune 500 Companies, and elite educational institutions, including Mayo Clinic, Mount Sinai Medical Center, UCLA, Johnson & Johnson, Boston Scientific, Celgene, Medtronic, St. Jude Medical, J.P. Morgan, and GE Healthcare.

As BioSig’s Chairman & CEO, my experience spans many decades and includes founding, running, and serving as Director to many key companies. In the 1990s, I was one of the leading growth stock investors with more than $3.5 billion in assets under management through J.W. Seligman & Co. Having supported emerging growth companies for over 25 years as a professional investor, I became an entrepreneur in 2002 and founded BioSig in 2009.

Additionally, I am surrounded by a team of equally impressive individuals that are committed to bringing their experience, knowledge and relationships to BioSig. I’m honored to introduce the following members of our stellar management team and world-class Board of Directors:

Mr. Joe Rafferty, Chief Commercialization Officer, brings to BioSig over 30 years of leadership experience with traditional corporate and emerging growth companies. Mr. Rafferty has created a legacy of building and leading highly successful teams with industry leaders like Pathway Medical, Avinger, ACS/Guidant, CR Bard Vascular/Cardiovascular, Synthes Spine, Sterilox, J&J's Ethicon Mechanical Products (Endo) and, most recently, as CEO of National Medical Sales, LLC.

Mr. Steve Chaussy, CFO, has acted as a consultant for small publicly traded entities with a special emphasis towards SEC reporting and compliance. Mr. Chaussy served as CFO for a large private distribution and wholesaling company, where he gained international experience.

Mrs. Natasha Russkina, VP of Business Development and Corporate Finance, has extensive experience in international business development, including 9 years at IG Group Plc, a British FTSE 250 company and a global leader in online trading. She was overseeing 12 European offices, which accounted for 45% of the Group’s revenue, and grew a new operational office in Eastern Europe from 14 members of staff to over 130. Natasha is based in Geneva, Switzerland, where we are growing our European operations.

Mr. David Weild IV, Director, is founder, Chairman and CEO of Weild & Co., Inc., parent company of the investment banking firm Weild Capital, LLC. Prior to Weild & Co., Mr. Weild was Vice Chairman of Nasdaq, president of PrudentialFinancial.com and head of corporate finance and equity capital markets at Prudential Securities, Inc. He is a recognized expert in capital markets and has spoken at the White House, Congress, the SEC, OECD and the G-20 on how market structure can be bettered to improve capital formation and economic growth.

Mr. Andrew L. Filler, Director, brings to BioSig over 20 years of experience in intellectual property for technology and medical device companies. He currently serves as Partner and General Counsel for Sherpa Technology Group since February 2014.  Mr. Filler’s extensive experience as an intellectual property lawyer and managing extensive intellectual property portfolios makes him a valuable member of our board.

Mr. Donald E. Foley, Director, brings extensive financial, economic, capital markets and executive leadership expertise to our board gained through his successful career on Wall Street and the Fortune 500. Mr. Foley has also been both a member and chairman of the Board of Trustees of Burke Rehabilitation Hospital in Westchester County, New York since 2005. Through his service in the healthcare sector, Mr. Foley has developed a strong appreciation for health care technology and the challenges and opportunities related to hospital administration.

Mr. Jeffrey F. O’Donnell, Sr, Director, has extensive experience in the Healthcare industry, merging a solid, traditional corporate background with emerging growth experience. Jeff brings more than 20 years of Board and Chief Executive experience running emerging medical device firms. Businesses under his direct leadership have achieved over $1.5 Billion in value creation from initial public offering of stock or mergers and acquisitions. 

Mr. Patrick J. Gallagher, MBA, CFA, Director, is an accomplished capital markets executive, advisor, and investor with a distinguished record of success in both the public and private markets. He has over 20 years of experience on Wall Street and extensive expertise in alternative investments, capital markets, and marketing. 

Mr. Roy T. Tanaka, Director, has served as the worldwide president of Biosense Webster, Inc., a Johnson & Johnson company, a market and technology leader in the field of electrophysiology. Mr. Tanaka brings broad experience in executive leadership in the medical device field. His operational expertise and knowledge of the regulatory environment brings a valuable perspective. 

Mr. Seth H.Z. Fischer, Director, most recently served as the Chief Executive Officer and as a director of Vivus, Inc., a publicly traded biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs. Prior to Vivus, Mr. Fischer served in positions of increasing responsibility with Johnson & Johnson from 1983 until his retirement in 2012.  

The countless accomplishments and years of experience of the management team, as well as the Board of Directors and Scientific Advisory Board, is unmatched, and provides BioSig with a clear advantage in the market. We are united by our passion to transform healthcare, growth mindset, dedication to quality, and successful track record at building companies.

Extensive biographies can be found on at:  https://www.biosigtech.com/about-biosig 

Kind regards,

Ken Londoner